Design of tRNALys3 Ligands: Fragment evolution and linker selection guided by NMR spectroscopy

Chemistry - A European Journal

Volumn 15, Issue 29, 2009, Pages 7109-7116

  Chung, Florence ^a   Tisné, Carine ^a   Lecourt, Thomas ^a   Seijo, Bili ^a   Dardel, Frédéric ^a   Micouin, Laurent ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Aminoglycoside mimics; Drug design; Fragment based synthesis; Rna recognition; Trna

Indexed keywords

BINDING ENERGY; CHELATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

AMINOGLYCOSIDES; BINDING AFFINITIES; DRUG DESIGN; LINKER REGION; OPTIMISATIONS; REVERSE TRANSCRIPTION; RNA RECOGNITION; TRNA;

LIGANDS;

AMINOACYL TRANSFER RNA; LIGAND; PEPTIDE FRAGMENT; TRANSFER RNA; TRNA, LYSINE; TRNA, LYSINE-;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METHODOLOGY; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE SEQUENCE; SYNTHESIS;

BASE SEQUENCE; BINDING SITES; DRUG DESIGN; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; RNA, TRANSFER; RNA, TRANSFER, AMINO ACYL;

EID: 67650632363     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.200802451     Document Type: Article

References (39)

1. S. B. Shuker, P. J. Hajduk, R. P. Meadows, S. W. Fesik, Science 1996, 274, 1531-1534.
2. a) D. C. Ress, M. Congreve, C. W. Murray, R. Carr, Nat. Rev. Drug Discovery 2004, 3, 660-672
3. b) D. A. Erlanson, R. S. McDowell, T. O'Brien, J. Med. Chem. 2004, 47, 3463-3482
4. c)D. A. Erlanson, Curr. Opin. Biotechnol. 2006, 47, 643-652
5. P. J. Hajduk, J. Greer, Nat. Rev. Drug Discovery 2007, 6, 211-219
6. e) Fragment-based Approaches in Drug Discovery (Eds: W. Jahnke, D. A. Erlanson), Wiley-VCH, Weinheim, 2006.
7. a) E. E. Swayze, E. A. Jefferson, K. A. Sannes-Lowery, L. B. Blyn, L. M. Risen, S. Arakawa, S. A. Osgood, S. A. Hofstadler, R. H. Grif-fey, J. Med. Chem. 2002, 45, 3816-3819;
8. b) L. Yu, T. K. Oost, J. M. Schkeryantz, J. Yang, D. Janowick, S. W. Fesik, J. Am. Chem. Soc. 2003, 125, 4444-4450;
9. c) M, Mayer, T.L. James, J. Am. Chem. Soc. 2004, 126, 4453-4460.
10. a) J. S. Mattick, Nat. Rev. Genet. 2004, 5, 317-323;
11. b) N. Foloppe, N. Matassova, F. Aboul-ela, Drug Discov. Today 2006, 11, 1019-1027.
12. J. R. Thomas, P. J. Hergenrother, Chem. Rev. 2008, 108, 1171-1224.
13. R. Marquet, C. Isel, C. Ehresmann, B. Ehresmann, Biochimie 1995, 77,113-124.
14. a) C. Tisné, Curr. HIV Res. 2005, 3, 147-156;
15. b) C. Tisné, B. Roques, F. Dardel, J. Biol. Chem. 2003, 279, 3588-3595;
16. c)P. Bar-raud, C. Gaudin, F. Dardel, C. Tisné, Biochimie 2007, 89, 1204-1210;
17. d) J. G. Levin, J. Guo, I. Rouzina, K, Musier-Forsyth, Prog. Nucleic Acid Res. Mol. Biol. 2005, 80, 217-286.
18. X. Wei, M, Götte, M. A. Wainberg, Prog. Nucleic Acid Res. Mol . Biol. 2000, 28, 3065-3074.
19. 3, which is a cellular rather than a viral target, is probably not a good choice for the design of a selective antiviral strategy. We, however, believe that targeting the discrete steps of the annealing process that occurs in the initiation of reverse transcription, which involves both viral and human RNAs could be a selective, less-toxic strategy
20. For a preliminary report, see: F. Chung, C. Tisné, T. Lecourt, F. Dardel, L. Micouin, Angew. Chem. 2007, 119, 4573-4575;
21. Angew. Chem. Int. Ed. 2007, 46, 4489-4491
22. C. Tisné, M. Rigourd, R. Marquet, C. Ehresmann, F. Dardel, RNA 2000, 6, 1403-1412.
23. C., Tisné, B. P. Roques, F. Dardel, J. Mol. Biol. 2001, 306, 443-454.
24. a) C. Tisné, F. Dardel, Comb. Chem. High Throughput Screening 2002, 5, 523-529;
25. b) C. Tisné, F. Guillière, F. Dardel, Biochimie 2005, 87, 885-888.
26. a) A. Pérez Luna, M.-A. Ceschi, M. Bonin, L. Micouin, H.-P. Husson, S. Gougeon, G. Estenne Bouthou, B. Marabout, M. Sevrin, P. George, J. Org. Chem. 2002, 67, 3522-3524;
27. b) A. Pérez Luna, M. Bonin, L. Micouin, H.-P. Husson, J. Am. Chem. Soc. 2002, 124, 12098-12099
28. This analogy between compound 1 and desoxystreptamine (DOS), the central core of aminoglycosides, has been recently confirmed by our group on a completely different target known to bind to aminoglycosides: the AAC6 1b aminoside-resistance enzyme: T. Lombes, G. Bégis, F. Maurice, S. Turcaud, T. Lecourt, F. Dardel, L. Micouin, ChemBioChem 2008, 9,1368-1371
29. a) W. P. Jencks, Proc. Natl. Acad. Sci. USA 1981, 78, 4046-4050;
30. b) C. W. Murray, M. L. Verdonk, J. Comput.-Aided Mol, Des. 2002, 16, 741-753;
31. c)C.H. Röhrig, C. Loch, J.-Y. Guan, G. Siegal, M. Overhand, ChemMedChem 2007, 2, 1054-1070.
32. Some degradation has been observed after prolonged storage (several months) at -20°C in a phosphate buffer solution.
33. For examples of stereospecifie interactions between small molecules and RNA, see:
34. a)M. Famulok, J. W. Szostak, J. Am. Chem. Soc. 1992, 114, 3990-3991;
35. b) I, Majerfeld, D. Puthenvedu, M, Yarus, J. Mol, Evol 2005, 61, 226-235.
36. P. Plateau, M. Guéron, J. Am, Chem, Soc. 1982, 104, 7310-7311
37. A. A. Szewczak, G. W. Kellogg, P. B. Moore, FEBS Lett. 1993, 327, 261-264.
38. J. Weigelt, J. Am. Chem. Soc. 1998, 120, 10778-10779.
39. F. Dardel, Comput. Appl Biosci. 1994, 10, 273-275.